Identifying and validating reliable biomarkers of response to CDK4/6 inhibitors for clinical and preclinical studies remains to be established; loss of p16 protein expression, Ki-67 index, CCND1 amplification, and cyclin D1 protein expression have been tested in other tumor types but are not reliable predictors [38]. This evidence concerns the gene MKI67 and neoplasm.